Table 3. . Preoperative multivariable Cox regression analyses predicting cancer-specific survival.
| Variables | Model 1 | Model 2 | Model 3 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | |
| Age cont. | 0.98 | 0.95–1.01 | 0.41 | 0.98 | 0.95–1.01 | 0.37 | 0.98 | 0.95–1.00 | 0.18 |
| Gender (males vs females) | 1.48 | 0.72–3.03 | 0.27 | 1.44 | 0.7–2.95 | 0.31 | 1.45 | 0.7–2.98 | 0.31 |
| BMI cont. | 0.91 | 0.83–0.99 | 0.04 | 0.92 | 0.84–1.01 | 0.09 | 0.94 | 0.86–1.03 | 0.2 |
| Hydronephrosis (no vs yes) | 2.02 | 1.08–3.76 | 0.02 | 1.6 | 0.85–3.02 | 0.14 | 1.75 | 0.93–3.31 | 0.08 |
| Hystology (pure vs nonpure UC) | 0.76 | 0.29–1.99 | 0.58 | 0.72 | 0.27–1.89 | 0.5 | 0.88 | 0.33–2.31 | 0.8 |
| NAC (3 cycles vs >3 cycles) | 1.13 | 0.6–2.12 | 0.68 | 1.12 | 0.6–2.09 | 0.7 | 1.13 | 0.6–2.11 | 0.69 |
| Stage, Tis/T1 | Ref. | Ref. | Ref. | ||||||
| T2 | 1.35 | 0.48–3.82 | 0.56 | 1 | 0.34–2.88 | 0.99 | 1.18 | 0.41–3.36 | 0.74 |
| T3 | 1.77 | 0.6–5.24 | 0.29 | 1.58 | 0.54–4.7 | 0.39 | 1.84 | 0.62–5.42 | 0.26 |
| T4 | 4.62 | 1.56–13.65 | 0.006 | 3.84 | 1.27–11.59 | 0.01 | 3.89 | 1.3–11.67 | 0.01 |
| Nodes + (no vs yes) | 0.99 | 0.34–2.87 | 0.99 | 1.03 | 0.35–2.97 | 0.95 | 0.85 | 0.29–2.45 | 0.76 |
| Metastasis + (no vs yes) | 1.44 | 0.18–11.21 | 0.72 | 1.29 | 0.16–10.12 | 0.8 | 1.44 | 0.18–11.19 | 0.72 |
| NLR (<3 vs >3) | - | - | - | 2.62 | 1.43–4.79 | 0.002 | - | - | - |
| NPAR (<18 vs >18) | - | - | - | - | - | - | 2.82 | 1.48–5.36 | 0.002 |
| Harrell’s C index | 67.2 | 70.2 | 71.57 | ||||||
Boldface values represent statistical significance.
C index: Concordance index; HR: Hazard ratio; NAC: Neoadjuvant chemotherapy; NLR: Neutrophil-to-lymphocyte ratio; NPAR: Neutrophil percentage-to-albumin ratio; Ref.: Reference; UC: Urothelial cancer.